S&P 500   4,290.89 (-1.07%)
DOW   33,715.62 (-0.86%)
QQQ   355.34 (-1.19%)
AAPL   172.54 (-2.01%)
MSFT   312.27 (-1.66%)
META   299.00 (-0.61%)
GOOGL   127.90 (-2.45%)
AMZN   127.44 (-2.92%)
TSLA   246.81 (-0.07%)
NVDA   421.20 (-0.24%)
NIO   8.49 (+1.68%)
BABA   86.08 (-1.31%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.51 (-0.56%)
MU   68.20 (-0.55%)
CGC   0.95 (+0.39%)
GE   109.99 (-1.55%)
DIS   80.52 (-0.60%)
AMC   8.17 (+0.37%)
PFE   32.87 (-0.33%)
PYPL   59.05 (+0.32%)
NFLX   382.43 (-0.62%)
S&P 500   4,290.89 (-1.07%)
DOW   33,715.62 (-0.86%)
QQQ   355.34 (-1.19%)
AAPL   172.54 (-2.01%)
MSFT   312.27 (-1.66%)
META   299.00 (-0.61%)
GOOGL   127.90 (-2.45%)
AMZN   127.44 (-2.92%)
TSLA   246.81 (-0.07%)
NVDA   421.20 (-0.24%)
NIO   8.49 (+1.68%)
BABA   86.08 (-1.31%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.51 (-0.56%)
MU   68.20 (-0.55%)
CGC   0.95 (+0.39%)
GE   109.99 (-1.55%)
DIS   80.52 (-0.60%)
AMC   8.17 (+0.37%)
PFE   32.87 (-0.33%)
PYPL   59.05 (+0.32%)
NFLX   382.43 (-0.62%)
S&P 500   4,290.89 (-1.07%)
DOW   33,715.62 (-0.86%)
QQQ   355.34 (-1.19%)
AAPL   172.54 (-2.01%)
MSFT   312.27 (-1.66%)
META   299.00 (-0.61%)
GOOGL   127.90 (-2.45%)
AMZN   127.44 (-2.92%)
TSLA   246.81 (-0.07%)
NVDA   421.20 (-0.24%)
NIO   8.49 (+1.68%)
BABA   86.08 (-1.31%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.51 (-0.56%)
MU   68.20 (-0.55%)
CGC   0.95 (+0.39%)
GE   109.99 (-1.55%)
DIS   80.52 (-0.60%)
AMC   8.17 (+0.37%)
PFE   32.87 (-0.33%)
PYPL   59.05 (+0.32%)
NFLX   382.43 (-0.62%)
S&P 500   4,290.89 (-1.07%)
DOW   33,715.62 (-0.86%)
QQQ   355.34 (-1.19%)
AAPL   172.54 (-2.01%)
MSFT   312.27 (-1.66%)
META   299.00 (-0.61%)
GOOGL   127.90 (-2.45%)
AMZN   127.44 (-2.92%)
TSLA   246.81 (-0.07%)
NVDA   421.20 (-0.24%)
NIO   8.49 (+1.68%)
BABA   86.08 (-1.31%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.51 (-0.56%)
MU   68.20 (-0.55%)
CGC   0.95 (+0.39%)
GE   109.99 (-1.55%)
DIS   80.52 (-0.60%)
AMC   8.17 (+0.37%)
PFE   32.87 (-0.33%)
PYPL   59.05 (+0.32%)
NFLX   382.43 (-0.62%)
NASDAQ:ALRN

Aileron Therapeutics (ALRN) Stock Forecast, Price & News

$1.46
-0.03 (-2.01%)
(As of 12:08 PM ET)
Compare
Today's Range
$1.44
▼
$1.49
50-Day Range
$1.49
▼
$1.87
52-Week Range
$1.12
▼
$5.64
Volume
3,485 shs
Average Volume
32,286 shs
Market Capitalization
$6.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

ALRN stock logo

About Aileron Therapeutics (NASDAQ:ALRN) Stock

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

ALRN Price History

ALRN Stock News Headlines

September 17, 2023 | americanbankingnews.com
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Growth in Short Interest
April 4, 2023 | finance.yahoo.com
Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
March 22, 2023 | finance.yahoo.com
Aileron Therapeutics, Inc. (ALRN)
March 14, 2023 | finance.yahoo.com
Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
March 3, 2023 | msn.com
Looking Into Aileron Therapeutics's Recent Short Interest
February 23, 2023 | markets.businessinsider.com
JonesTrading Keeps Their Hold Rating on Aileron Therapeutics (ALRN)
February 22, 2023 | finance.yahoo.com
Cancer drugmaker down to 3 employees after trial failure
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
February 21, 2023 | msn.com
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.06%
February 21, 2023 | seekingalpha.com
Aileron off 38% on plans to explore sale after setback for cancer candidate
February 21, 2023 | finance.yahoo.com
Aileron Therapeutics Shelves Development On Chemoprotection Agent, Shares Fall
February 21, 2023 | markets.businessinsider.com
Aileron Terminates Phase 1b Breast Cancer Chemoprotection Trial Of ALRN-6924
February 21, 2023 | marketwatch.com
Aileron Therapeutics Shares Slide to New Low on Lead Drug Failure >ALRN
February 21, 2023 | marketwatch.com
Aileron Exploring Options After ALRN-6924 Study Failure >ALRN
January 17, 2023 | reuters.com
alrn.a - | Stock Price & Latest News | Reuters
December 29, 2022 | msn.com
What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock
November 30, 2022 | finance.yahoo.com
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements
November 24, 2022 | finance.yahoo.com
Aileron Therapeutics, Inc. (ALRN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
November 10, 2022 | finanznachrichten.de
Aileron Therapeutics, Inc.: Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split
November 10, 2022 | finance.yahoo.com
Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split
November 4, 2022 | finance.yahoo.com
Aileron Therapeutics, Inc. (ALRN) Moves to Buy: Rationale Behind the Upgrade
November 1, 2022 | technews.tmcnet.com
Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
November 1, 2022 | finance.yahoo.com
Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
October 26, 2022 | finance.yahoo.com
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference
September 30, 2022 | finance.yahoo.com
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022
September 22, 2022 | finance.yahoo.com
Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference
See More Headlines
Receive ALRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALRN Company Calendar

Last Earnings
8/11/2023
Today
9/26/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALRN
CUSIP
N/A
CIK
1420565
Web
www.aileronrx.com
Phone
(617) 995-0900
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-27,330,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-96.27%
Return on Assets
-81.90%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.66
Quick Ratio
11.66

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.10 per share
Price / Book
0.36

Miscellaneous

Outstanding Shares
4,540,000
Free Float
4,382,000
Market Cap
$6.76 million
Optionable
Not Optionable
Beta
2.13
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Manuel C. Aivado M.D. (Age 53)
    Ph.D., Pres, CEO & Director
    Comp: $700.57k
  • Dr. D. Allen Annis Ph.D. (Age 50)
    Sr. VP of Research
    Comp: $422.01k
  • Ms. Susan L. Drexler CPA (Age 53)
    M.B.A., Interim CFO, Principal Financial Officer & Principal Accounting Officer

Key Competitors

View All Competitors













ALRN Stock - Frequently Asked Questions

How have ALRN shares performed in 2023?

Aileron Therapeutics' stock was trading at $2.37 at the beginning of 2023. Since then, ALRN shares have decreased by 37.1% and is now trading at $1.49.
View the best growth stocks for 2023 here.

Are investors shorting Aileron Therapeutics?

Aileron Therapeutics saw a increase in short interest in August. As of August 31st, there was short interest totaling 6,300 shares, an increase of 40.0% from the August 15th total of 4,500 shares. Based on an average daily trading volume, of 21,200 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.2% of the shares of the company are sold short.
View Aileron Therapeutics' Short Interest.

When is Aileron Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our ALRN earnings forecast.

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics, Inc. (NASDAQ:ALRN) posted its earnings results on Friday, August, 11th. The company reported ($0.39) EPS for the quarter.

When did Aileron Therapeutics' stock split?

Shares of Aileron Therapeutics reverse split before market open on Thursday, November 10th 2022. The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Aileron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), OPKO Health (OPK), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Lexicon Pharmaceuticals (LXRX) and Nabriva Therapeutics (NBRV).

When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an initial public offering on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

How do I buy shares of Aileron Therapeutics?

Shares of ALRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aileron Therapeutics' stock price today?

One share of ALRN stock can currently be purchased for approximately $1.49.

How much money does Aileron Therapeutics make?

Aileron Therapeutics (NASDAQ:ALRN) has a market capitalization of $6.76 million.

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The official website for the company is www.aileronrx.com. The company can be reached via phone at (617) 995-0900 or via email at hans@lifesciadvisors.com.

This page (NASDAQ:ALRN) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -